About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our research group is focused on studying the pathophysiology of migraine and other primary headaches using preclinical, translational and clinical research.
Migraine will allow us to define the brain’s adaptive, sensory/cognitive functions, through genetics, epigenetics, neurophysiology, neuromolecular and neuroanatomical information with an interest in developing clinical therapeutic solutions, with the goal on having an impact on suffering and increasing the well-being.
IP: Patricia Pozo Rosich Collaborators: Alicia Alpuente Ruiz, Laila Asskour, Eulalia Gine Cipres, Marta Torres Ferrús, Victor José Gallardo Lopez Funding agency: Instituto de Salud Carlos III Funding: 99999.97 Reference: AC19/00124 Duration: 01/01/2020 - 30/06/2024
PMID: 33772636 Journal: JOURNAL OF NEUROLOGY Year: 2021 Reference: J Neurol. 2021 Oct;268(10):3789-3798. doi: 10.1007/s00415-021-10523-8. Epub 2021 Mar 27. Impact factor: 4.849 Publication type: Paper in international publication Authors: Torres-Ferrus, Marta, Gallardo, Victor J, Alpuente, Alicia, Caronna, Edoardo, Gine-Cipres, Eulalia, Pozo-Rosich, Patricia et al. DOI: 10.1007/s00415-021-10523-8
PMID: 33730441 Journal: EUROPEAN JOURNAL OF NEUROLOGY Year: 2021 Reference: Eur J Neurol. 2021 Jul;28(7):2378-2382. doi: 10.1111/ene.14828. Epub 2021 Apr 5. Impact factor: 6.089 Publication type: Letter whit IF Authors: Pozo-Rosich, Patricia, Torres-Ferrus, Marta, Caronna, Edoardo, Gallardo, Victor J, Alpuente, Alicia et al. DOI: 10.1111/ene.14828
PMID: 32838536 Journal: CEPHALALGIA Year: 2021 Reference: Cephalalgia. 2021 Jan;41(1):45-57. doi: 10.1177/0333102420951509. Epub 2020 Aug 24. Impact factor: 6.295 Publication type: Paper in international publication Authors: Pozo-Rosich, Patricia, Vila-Ballo, Adria, Marti-Marca, Angela, Torres-Ferrus, Marta, Alpuente, Alicia, Gallardo, Victor Jose et al. DOI: 10.1177/0333102420951509
Two international studies led by Vall d'Hebron recommend early administration of specific drugs to prevent migraine to achieve a better response to therapy.
On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.
The study, conducted in more than 770 people, concludes that atogepant reduces the frequency of migraine attacks and the need to take medication.
